The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 324.00
Bid: 324.50
Ask: 326.00
Change: -1.50 (-0.46%)
Spread: 1.50 (0.462%)
Open: 320.00
High: 329.00
Low: 320.00
Prev. Close: 325.50
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

SMALL-CAP WINNERS & LOSERS: Oxford BioMedica bullish; Petrofac slumps

Mon, 29th Apr 2024 10:42

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Monday.

----------

SMALL-CAP - WINNERS

----------

Oxford BioMedica PLC, up 6.9% at 244.25 pence, 12-month range 164.29p-474.50p. The gene and cell-therapy company says it is seeing decent demand for its contract development and manufacturing organisation offering, as it moves away from the Covid-19 vaccine era. Oxford BioMedica's revenue in 2023 falls 36% to GBP89.5 million from GBP140.0 million and its pretax loss stretches to GBP188.5 million from GBP46.0 million. Hurting its bottom line is a GBP99.3 million impairment of assets booked in the US business, "driven by the cessation of revenues from Homology". Homology Medicines Inc is a genetic medicines company and client of Oxford Biomedica US. More promisingly, Oxford BioMedica reports a "small increase in core business" revenue. Chief Executive Officer Frank Mathias comments: "2023 was a year of transformation for Oxford Biomedica. We are building our position as a global pure-play cell and gene therapy CDMO and through our 'One OXB' strategy are unifying our operations in the UK, US and the EU, including our newly-acquired sites in France...Despite challenging market conditions, we continue to see strong demand for our CDMO services, further solidifying our position as a world-leading global CDMO in the rapidly expanding cell and gene therapy market."

----------

Digital 9 Infrastructure PLC, up 3.9% at 22.03 pence, 12-month range 14.50p-72.00p. The investor in internet infrastructure, such as data centres and subsea fibre receives a USD25 million deferred consideration payment in connection with its sale of Verne Global. Digital 9 plans an additional GBP47 million repayment and partial cancellation of its revolving credit facility.

----------

SMALL-CAP - LOSERS

----------

Petrofac Ltd, down 31% at 15.46p, 12-month range 13.91p-87.50p. It warns a financial restructuring could see a chunk of its debt converted to equity, resulting in dilution of existing shareholders. The energy infrastructure company also flags an extra USD130 million charge in its engineering and construction division and said the release of full-year results would be delayed.

----------

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
16 Apr 2021 09:49

BROKER RATINGS: RBC upgrades WH Smith and downgrades Dixons Carphone

BROKER RATINGS: RBC upgrades WH Smith and downgrades Dixons Carphone

Read more
15 Apr 2021 09:02

Oxford Biomedica swings to EBITDA profit

(Sharecast News) - Oxford Biomedica reported a 37% improvement in total revenues in its preliminary results on Thursday, to £87.7m.

Read more
15 Apr 2021 09:00

Oxford BioMedica annual revenue leaps on AstraZeneca vaccine deal

Oxford BioMedica annual revenue leaps on AstraZeneca vaccine deal

Read more
8 Apr 2021 16:05

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
6 Apr 2021 08:19

Oxford Biomedica signs viral vectors pact with Boehringer Ingelheim

Oxford Biomedica signs viral vectors pact with Boehringer Ingelheim

Read more
6 Apr 2021 08:08

Oxford Biomedica strikes three-year deal with Boehringer Ingelheim

(Sharecast News) - Gene and cell therapy company Oxford Biomedica has signed a new three-year development and supply agreement with Boehringer Ingelheim, it announced on Tuesday, for the manufacture and supply of various types of viral vectors.

Read more
6 Apr 2021 07:53

LONDON MARKET PRE-OPEN: Returns in store for BP shareholders

LONDON MARKET PRE-OPEN: Returns in store for BP shareholders

Read more
21 Mar 2021 20:57

EU rebuffs UK calls to ship AstraZeneca COVID vaccines from Europe

By Francesco GuarascioBRUSSELS, March 21 (Reuters) - The European Union is rebuffing British government calls to ship AstraZeneca COVID-19 vaccines produced in a factory in the Netherlands, an EU official said on Sunday.Former EU member Britain ha...

Read more
19 Mar 2021 10:29

Sanofi to terminate haemophilia development pact with Oxford Biomedica

Sanofi to terminate haemophilia development pact with Oxford Biomedica

Read more
19 Mar 2021 07:50

Oxford Biomedica says Sanofi pulling out of haemophilia project

(Sharecast News) - Oxford Biomedica said that Sanofi's decision to terminate collaboration on a haemophilia treatment would have a "negligible" impact on revenue.

Read more
3 Feb 2021 13:56

IN BRIEF: Oxford Biomedica Adds Genetics Professor To Non-Exec Team

IN BRIEF: Oxford Biomedica Adds Genetics Professor To Non-Exec Team

Read more
29 Jan 2021 09:11

UPDATE 1-EU holds out for more after AstraZeneca offered 8 mln extra COVID-19 shots

* Astra had committed to at least 80 mln shots in Q1* EU funded two UK plants under deal with Astra - sources* Astra says UK has priority for doses produced there (Adds detail, background)By Francesco Guarascio and Sabine SieboldBRUSSELS, Jan 29 (Re...

Read more
18 Jan 2021 17:18

IN BRIEF: Oxford Biomedica's Facility In Oxford Now Formally Opened

IN BRIEF: Oxford Biomedica's Facility In Oxford Now Formally Opened

Read more
8 Jan 2021 09:40

UK BROKER RATINGS SUMMARY: Shore Says Buy Hargreaves; UBS Cuts Next

UK BROKER RATINGS SUMMARY: Shore Says Buy Hargreaves; UBS Cuts Next

Read more
8 Dec 2020 12:31

UK's initial AstraZeneca shots will come from Europe, taskforce says

By Alistair SmoutLONDON, Dec 8 (Reuters) - Britain's initial doses of the COVID-19 vaccine candidate developed by AstraZeneca and Oxford University will come from Europe rather than a domestic supply chain, the country's Vaccine Taskforce said.The...

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.